🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Barakaldo
Clinical trial register · Spain

Clinical Trials in Barakaldo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5885 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:52 UTC
5885
Studies in scope
all four open statuses
3103
Recruiting now
open to new participants
1139
Lead sponsors
across recruiting studies
Top sites
Barcelona 3233 Madrid 3015 Valencia 1201 Seville 1055 Málaga 741
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca10 Fundación EPIC9 Sanofi5 Janssen Research & Development, LLC5 Hoffmann-La Roche4
Site location
Barcelona3233 Madrid3015 Valencia1201 Seville1055 Málaga741
All 455 locations
Target enrolment
to

Trials with a site in Barakaldo

142 of 5885 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
NCT07460986Soft Tissue Sarcoma (STS)
DrugsBexmarilimab·Doxorubicin
MedSIR
Phase 1/2
278
Badalona, Barakaldo, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Zaragoza
2026-08-20
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Badalona, Barakaldo, Barcelona, Huelva, L'Hospitalet Del Llobregat, Madrid, Sabadell, Valencia
2026-07-27
Active, closed
Is Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study)
NCT07708506Acute Hypoxemic Respiratory Failure
Jesus Villar
Observational
1,241
Barakaldo, Albacete, Barcelona, León, Madrid, Murcia, Valencia, Valladolid
2026-07-13
Recruiting
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991Acute Myeloid Leukemia, Adult
DrugsQuizartinib·Azacitidine·Venetoclax
PETHEMA Foundation
Phase 3
376
Santiago de Compostela, Hospitalet Del Llobregat, Terrassa, Jaén, Alcalá de Henares, San Sebastián de los Reyes, Málaga, Barakaldo
2026-07-02
Not yet open
Scaling up the Integrated Care Pathway for Acute Asthma to All Osakidetza Pediatric Services Through a Cluster-randomized SMART Design
NCT07642388Asthma in Children
Basque Health Service
Not applicable
4,680
Barakaldo
2026-07-01
Not yet open
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
NCT07665853Preeclampsia
Hospital Universitari Vall d'Hebron Research Institute
Phase 3
15,160
Granada, Barcelona, Girona, Tarragona, Barakaldo, A Coruña, Alicante, Burgos
2026-07-01
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Barakaldo, Barcelona, Madrid, Oviedo, Seville
2026-07-01
Not yet open
Reduction of Low-value Prescribing Through Audit and Feedback
NCT07336550Inappropriate Prescribing, Implementation Science, Behavioral Sciences
Basque Health Service
Not applicable
540
Barakaldo
2026-06
Recruiting
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
NCT07313176Advanced Parkinson Disease
Britannia Pharmaceuticals Ltd.
Observational
215
A Coruña, Seville, Toledo, Barakaldo, Bilbao
2026-05-08
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
876
L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville
2026-05-04
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
L'Hospitalet Del Llobregat, Barcelona, Madrid, Valencia, Barakaldo, Málaga, Seville, Zaragoza
2026-03-16
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Barcelona, Barakaldo, Jaén, Madrid, Málaga, Murcia
2026-03-12
Recruiting
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150Metastatic Castration-Resistant Prostate Cancer
DrugsInavolisib·Abiraterone·Enzalutamide·Docetaxel
Hoffmann-La Roche
Phase 2
100
Barakaldo, Córdoba, Madrid, Valencia
2026-03-11
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Lleida, Pozuelo de Alarcón, El Palmar, Vigo, Barakaldo
2026-03-10
Recruiting
Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial
NCT07015892Small Cell Lung Carcinoma
Instituto de Investigación Biomédica de Salamanca
Phase 3
300
Salamanca, Almería, Barakaldo, Girona, Las Palmas de Gran Canaria, Madrid, Murcia, Santander
2026-03-01
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia
NCT07448285Chronic Pain
Biobizkaia Health Research Institute
Phase 3
86
Barakaldo, Bilbao
2026-02-24
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
DrugTenecteplase
Boehringer Ingelheim
Phase 3
1,325
A Coruña, Alicante, Barakaldo, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca
2026-02-17
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia
2026-02-05
Recruiting
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717Non-Small Cell Lung Cancer
DrugCemiplimab
ETOP IBCSG Partners Foundation
Phase 3
390
A Coruña, Alicante, Barakaldo, Barcelona, Granada, Jerez de la Frontera, Madrid, Santa Cruz de Tenerife
2026-01-12
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Barakaldo, Esplugues de Llobregat, Madrid
2026-01-12
Recruiting
Tuvusertib in Astrocytoma With ATRX Mutation
NCT07417761Astrocytoma
DrugTuvusertib
Grupo Español de Investigación en Neurooncología
Phase 2
56
Palma de Mallorca, Barcelona, Barakaldo, Granada, Madrid, Vigo, Salamanca, Seville
2025-12-19
Recruiting
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
NCT07190690Coronary Artery Disease
Fundación EPIC
Not applicable
2,100
Alicante, Badalona, Barakaldo, Barcelona, Castelló, Donostia / San Sebastian, El Palmar, Fuencarral-El Pardo
2025-12-19
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Badajoz, Badalona, Barakaldo, Barcelona, Córdoba, Elche, Girona, Hospitalet
2025-12-12
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
Barakaldo, Seville
2025-11-25
Recruiting
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure
Takeda
Observational
10
L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-11-03
Recruiting
TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
NCT07284277Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2
30
Pamplona, Barakaldo, Galdakao, Madrid, Vitoria-Gasteiz
2025-10-14
Active, closed
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
NCT06992609Small Cell Lung Carcinoma
DrugDurvalumab
AstraZeneca
Phase 3
68
A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander
2025-09-15
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Seville, Barcelona, Barakaldo, Madrid
2025-08-26
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
DrugMezagitamab
Takeda
Phase 3
347
Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville
2025-07-15
Recruiting
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
NCT06315010NSCLC, Brain Metastases, ROS1 Gene Rearrangement
DrugRepotrectinib
MedSIR
Phase 2
20
Elche, Barcelona, Girona, Madrid, Reus, Alicante, Barakaldo, León
2025-06-27
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-23
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga
2025-05-19
Recruiting
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection
DrugsFosfomycin·Aztreonam·Ceftazidime-avibactam·Meropenem
National University of Singapore
Phase 4
600
Alicante, Badajoz, Barakaldo, Barcelona, Córdoba, Granada, Madrid, Málaga
2025-04-21
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Alicante, Barakaldo, Barcelona, Granada, Madrid, Manises, Santiago Compostela, Seville
2025-04-15
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Alcorcón, Alzira (Valencia), Badalona, Barakaldo, Barcelona, Burgos, Cáceres, Granada
2025-03-28
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville
2025-03-18
Recruiting
Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke
NCT05930145Stroke, Thrombectomy, Arterial Occlusive Diseases
Fundación EPIC
Not applicable
200
Barakaldo, Oviedo, Valladolid
2025-03-14
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Córdoba, Barcelona, Sabadell, Barakaldo, Santander, Lugo, Madrid, Majadahonda
2025-03-13
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Barakaldo, Santander, Badajoz, Las Palmas, Madrid, Sevilla, Marbella, Seville
2025-02-27
Not yet open
A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy
NCT06784115Prostate Cancer Patients Treated by Radiotherapy
University Hospital Schleswig-Holstein
Not applicable
27
Barakaldo
2025-02-15
Recruiting
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT06686615Primary Hypercholesterolemiia, Mixed Dyslipidemia
DrugsBempedoic acid·Ezetimibe·Rosuvastatin·Atorvastatin
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,000
Albacete, Alicante, Barakaldo, Burgos, Cadiz, Cantabria, Córdoba, Donostia / San Sebastian
2025-02-12
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Seville, L'Hospitalet de Llobregat, Barakaldo, Las Palmas de Gran Canaria, Majadahonda, Gijón, Alicante, Barcelona
2025-01-27
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
San Sebastián, Barakaldo, Barcelona, Madrid, Móstoles, Seville
2025-01-17
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Barakaldo, Barcelona, Madrid
2025-01-10
Recruiting
Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).
NCT07814924Chronic Rhinosinusitis With Nasal Polyps
DrugMepolizumab
Instituto de Investigación Marqués de Valdecilla
Phase 4
75
Barakaldo, Jerez de la Frontera, Madrid, Salamanca, Santander, Seville, Valladolid
2024-12-31
Active, closed
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
NCT06746116Advanced or Recurrent Endometrial Cancer
DrugDurvalumab
AstraZeneca
Phase 3
45
A Coruña, Alicante, Barakaldo, Barcelona, Córdoba, El Palmar, Girona, L'Hospitalet de Llobregat
2024-12-30
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Seville, Barcelona, Madrid, Barakaldo
2024-12-11
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barakaldo, A Coruña, Las Palmas de Gran Canaria, Majadahonda, Marbella
2024-12-03
Recruiting
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
DrugNiraparib
MedSIR
Phase 2
30
A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo
2024-12-03
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén
2024-11-19
Recruiting
Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
NCT06423898Endocarditis, Infective
DrugAmpicillin
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 4
284
Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga
2024-10-09
Recruiting
Efficacy of INM004 in Children With STEC-HUS
NCT06389474Hemolytic-Uremic Syndrome
Inmunova S.A.
Phase 3
220
Barakaldo, Madrid
2024-10-05
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Datopotamab Deruxtecan·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga
2024-10-04
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugTEV-56286
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
Barakaldo, Barcelona, Elche, Madrid, Pamplona, Seville, Valencia
2024-10-02
Active, closed
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027Parkinson Disease
Cerevance
Phase 3
330
Seville, Sant Cugat del Vallès, Barakaldo, San Sebastián, Valencia, Barcelona, Madrid
2024-09-20
Active, closed
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
NCT06790238Adenocarcinoma of Stomach, Critical Pathways, Enhanced Recovery After Surgery (ERAS) Protocol, Retrospective Studies
Grupo Español de Rehabilitación Multimodal
Observational
350
Alcázar de San Juan, Barakaldo, Barcelona, Bilbao, Ciudad Real, Fuenlabrada, Guadalajara, Inca
2024-09-01
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia
2024-07-23
Recruiting
Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
NCT06582628Metastatic Prostate Cancer
DrugEnzalutamide
Fundacion Oncosur
Phase 2
78
Badalona, Sabadell, Santander, Cadiz, Barakaldo, Barcelona, Madrid, Málaga
2024-07-05
Not yet open
Understanding Lung Cancer Related Risk Factors and Their Impact
NCT06473870Lung Cancer Screening
Biobizkaia Health Research Institute
Observational
6,160
Barakaldo, Seville
2024-07
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
A Coruña, Badalona, L'Hospitalet Del Llobregat, Barakaldo, Santa Cruz de Tenerife, Donostia / San Sebastian, Majadahonda, El Palmar, Murcia
2024-06-19
Recruiting
Virtual Rehabilitation Platform for Patients With Knee Prothesis
NCT06720779Knee Arthropathy
Trak Health Solutions S.L.
Not applicable
20
Barakaldo
2024-06-05
Recruiting
Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections
Biobizkaia Health Research Institute
Observational
1,500
A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos
2024-04-26
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid
2024-04-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt
2024-04-16
Active, closed
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT06321757Coronary Artery Disease
Fundación EPIC
Observational
501
Albacete, Alicante, Barakaldo, Boadilla del Monte, Ciudad Real, Granada, Huelva, L'Hospitalet de Llobregat
2024-02-26
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
DrugDurvalumab
AstraZeneca
Phase 2
142
Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza
2024-02-22
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Alicante, Badia Del Vallès, Barakaldo, Barcelona, Castro Urdiales, Córdoba, Granada, Madrid
2024-02-21
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide
Pfizer
Phase 3
492
Badalona, Terrassa, Barakaldo, Barcelona, Murcia, Girona, Valencia, Madrid
2024-02-08
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Alicante, Barakaldo, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia
2024-01-17
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Murcia, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Donostia / San Sebastian, Girona, Las Palmas de Gran Canaria, Lleida
2023-12-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
A Coruña, Badajoz, Barakaldo, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, León
2023-12-21
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Alicante, Barakaldo, El Palmar, Girona, Granada, L'Hospitalet de Llobregat, Lleida, Madrid
2023-12-15
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Murcia, Barcelona, Barakaldo, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Pontevedra, Seville, Córdoba
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
DrugsPrednisone/Prednisolone·Odronextamab·Bendamustine·Vincristine
Regeneron Pharmaceuticals
Phase 3
822
Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón
2023-12-12
Active, closed
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364Follicular Lymphoma (FL)
DrugsOdronextamab·Vincristine·Doxorubicin·Rituximab
Regeneron Pharmaceuticals
Phase 3
733
Seville, Sabadell, Terrassa, Barakaldo, Majadahonda, Pozuelo de Alarcón, Pamplona, Oviedo
2023-11-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Pemetrexed·Nivolumab
AstraZeneca
Phase 3
863
Barakaldo, Barcelona, Madrid, Oviedo
2023-11-09
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cadiz, Cáceres
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon
2023-10-05
Active, closed
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Urothelial Carcinoma
DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Badalona, L'Hospitalet de Llobregat, Barakaldo, Santander, Majadahonda, Badajoz, Barcelona, L'Hospitaler de Llobregat
2023-09-22
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 2
144
Barakaldo, Barcelona, Burgos, Madrid
2023-08-25
Recruiting
Coroflex® ISAR NEO PMCF Study
NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease
Fundación EPIC
Observational
3,000
A Coruña, Badajoz, Badalona, Barakaldo, Barcelona, Cáceres, Ciudad Real, Huelva
2023-08-04
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Terrassa, Barakaldo, Madrid
2023-06-27
Active, closed
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472Paroxysmal Nocturnal Hemoglobinuria
DrugPegcetacoplan
Swedish Orphan Biovitrum
Observational
165
Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria
2023-06-26
Recruiting
A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT05769621Propionic Acidemia
ModernaTX, Inc.
Observational
60
Esplugues de Llobregat, Santander, Barakaldo, Madrid, Seville, Valencia
2023-06-16
Recruiting
SUPRAFLEX CRUZ PMCF Study ( rEpic05 )
NCT05617599Coronary Artery Disease (CAD), Ischemic Heart Disease
Fundación EPIC
Observational
508
Elche, A Coruña, Barakaldo, Barcelona, Castelló, Cáceres, Ciudad Real, Girona
2023-05-10
Recruiting
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100Focal Onset Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
360
Barakaldo, Madrid
2023-05-09
Recruiting
Asthma Crisis in Paediatrics: Impact of a Care Pathway in Primary and Hospital Care
NCT06437444Asthma in Children, Implementation Science
Basque Health Service
Not applicable
249
Barakaldo
2023-05-07
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Barakaldo, Barcelona, Madrid, Málaga, Valencia, Valladolid
2023-04-25
Active, closed
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359Parkinson's Disease
Bial R&D Investments, S.A.
Phase 2
237
Badalona, Barakaldo, Barcelona, Madrid, Seville
2023-03-31
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
A Coruña, Albacete, Alcoy, Alicante, Alzira, Badajoz, Badalona, Barakaldo
2023-03-31
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Childhood Idiopathic Nephrotic Syndrome
DrugsAcetaminophen/Paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab
Hoffmann-La Roche
Phase 3
85
Espluges de Llobregat, Barakaldo
2023-03-29
Active, closed
Sequent Extended Study
NCT05788432Coronary Artery Disease, Ischemic Heart Disease
Fundación EPIC
Observational
2,040
Alava, Alicante, Badajoz, Badalona, Barakaldo, Barcelona, Cadiz, Castelló
2023-03-28
Recruiting
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05781217Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 3
534
L'Hospitalet de Llobregat, Fuenlabrada, Pozuelo de Alarcón, Barakaldo, Barcelona, Madrid, Tarragona, Valencia
2023-03-14
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugTovorafenib
Day One Biopharmaceuticals, Inc.
Phase 3
418
Barakaldo, Barcelona, Madrid, Seville, Valencia
2023-02-27
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona
2023-02-15
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Barakaldo, Badajoz, Barcelona, Burgos, Madrid, Seville, Valencia
2023-02-03
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654Triple Negative Breast Cancer
DrugsSacituzumab Govitecan·Capecitabine·Pembrolizumab
Gilead Sciences
Phase 3
1,514
A Coruña, Badalona, Barakaldo, Barcelona, Castellon, Cáceres, Córdoba, Donostia / San Sebastian
2022-12-12
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Barakaldo, Barcelona, Jerez de la Frontera, Madrid, Murcia, Sabadell, Seville, Valencia
2022-11-23
Recruiting
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
NCT05398679Endocarditis Infective
DrugsCefaclor·Dicloxacillin·Clindamycin·Ciprofloxacin
Fundacion Clinic per a la Recerca Biomédica
Phase 4
360
Alicante, Seville, Palma de Mallorca, Barcelona, Sabadell, Terrassa, Barakaldo, Santander
2022-08-17
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo
2022-08-08
Rows per page Showing 1–100 of 142
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-spain/city/barakaldo

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,885 studies in total at the last sync on 26 Sep 2026, 19:52 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 142 of those studies with a site in Barakaldo.

How many clinical trials are recruiting in Barakaldo?

81 of the 142 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:52 UTC sync. A further 5 have not yet opened recruitment, 55 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barakaldo), 142 studies
PhaseStudiesRecruitingShare
Phase 3734051.4%
Observational291720.4%
Phase 2171012%
Not applicable946.3%
Phase 4644.2%
Phase 1/2553.5%
Phase 2/3312.1%

Most active sponsors

Lead sponsors with the most studies (Barakaldo)
Lead sponsorStudiesRecruiting
AstraZeneca105
Fundación EPIC94
Janssen Research & Development, LLC50
Sanofi50
Eli Lilly and Company44
Hoffmann-La Roche42
ModernaTX, Inc.44
Basque Health Service31
Biobizkaia Health Research Institute32
Bristol-Myers Squibb33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.